Drug Profile
CTLA4-Ig - Pharmacia
Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action CD28 antigen inhibitors; CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 09 Mar 1999 No-Development-Reported for Rheumatoid arthritis (Unknown route)
- 10 Apr 1996 Preclinical development for Rheumatoid arthritis (Unknown route)